Company: Vifor Pharma
Job title: Medical Strategy & Portfolio Lead
Claudio Mori is the Medical Strategy/Portfolio Lead and Global Medical Lead Ferroportn‐Inhibitor, Director, at Vifor Pharma Ltd, Zurich, Switzerland. He graduated from the University of Zurich Medical School, Switzerland. After basic research in Microbiology and clinical experience in General and Internal Medicine, always focusing on Cardiology, he joined the pharmaceutical industry as Medical Advisor Cardiovascular at Bristol Myers Squibb GmbH, Baar, Switzerland. In this position, he was responsible for the products pravastatin, irbesartan and about 15 cardiovascular compounds (no promotion). Before moving to Vifor Pharma, he worked as Regional Medical Liaison CV&Rheumatology in Spain/Portugal for Centocor B.V., Leiden, Netherlands, responsible for abciximab and infliximab, respectively. In Vifor Pharma, he started in the Clinical Development being responsible for starting and developing Cardiology by designing FAIR‐HF, CONFIRM‐HF, EFFECT‐HF and implementing and comprehensive IIT study program, developing further Nephrology by designing the FIND‐CKD and Gastroenterology the FERGICore, FERGIMain studies. He started to build up the Medical Affairs functions and subsequently been appointed as Medical Affairs Director Cardiology and Nephrology to launch ferric carboxymaltose (Ferinject®). Lastly, Claudio Mori was responsible as the Scientific Advisor Cardiovascular for the strategy and life cycle management in regards of data generation and clinical study plan for patiromer, a novel potassium‐binder. The current role as Medical Strategy and Portfolio Lead includes the oversight, development, inputs into the product and portfolio strategy, support to clinical development activities as well as team and matrix management.